These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 12120185)

  • 1. Tegaserod for the treatment of constipation-predominant irritable bowel syndrome.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(4):187-98. PubMed ID: 12120185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB; Wilhelm SM
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
    Beglinger C
    Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug therapy options for patients with irritable bowel syndrome.
    Talley NJ
    Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tegaserod in treatment of women with irritable bowel syndrome].
    Munck LK; Ainsworth MA
    Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
    Fidelholtz J; Smith W; Rawls J; Shi Y; Zack A; Rüegg P; Lefkowitz M
    Am J Gastroenterol; 2002 May; 97(5):1176-81. PubMed ID: 12014724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: the safety profile of tegaserod.
    Schoenfeld P
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():25-30. PubMed ID: 15521852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: tegaserod for chronic constipation.
    Johanson JF
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():20-4. PubMed ID: 15521851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies.
    Quigley EM; Wald A; Fidelholtz J; Boivin M; Pecher E; Earnest D
    Clin Gastroenterol Hepatol; 2006 May; 4(5):605-13. PubMed ID: 16678076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
    Reilly MC; Barghout V; McBurney CR; Niecko TE
    Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tegaserod on gut transit in male and female subjects.
    Degen L; Petrig C; Studer D; Schroller S; Beglinger C
    Neurogastroenterol Motil; 2005 Dec; 17(6):821-6. PubMed ID: 16336497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
    Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tegaserod and other serotonergic agents: what is the evidence?
    Chey WD
    Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tegaserod maleate (Zelnorm) for IBS with constipation.
    Med Lett Drugs Ther; 2002 Sep; 44(1139):79-80. PubMed ID: 12237618
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.
    Tougas G; Snape WJ; Otten MH; Earnest DL; Langaker KE; Pruitt RE; Pecher E; Nault B; Rojavin MA
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1701-8. PubMed ID: 12269961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study.
    Kamm MA; Müller-Lissner S; Talley NJ; Tack J; Boeckxstaens G; Minushkin ON; Kalinin A; Dzieniszewski J; Haeck P; Fordham F; Hugot-Cournez S; Nault B
    Am J Gastroenterol; 2005 Feb; 100(2):362-72. PubMed ID: 15667494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.
    Wagstaff AJ; Frampton JE; Croom KF
    Drugs; 2003; 63(11):1101-20. PubMed ID: 12749744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation.
    Al-Judaibi B; Chande N; Gregor J
    Can J Clin Pharmacol; 2010; 17(1):e194-200. PubMed ID: 20410554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: tegaserod -- the global experience.
    Chey WD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():15-9. PubMed ID: 15521850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.